Table 2:

Clinical trials in LKB1/STK11 mutant cancer

ClinicalTrials.gov ID	Drug(s)	Target(s)	Cancer	Status
NCT03709147	Metformin +/− fasting mimicking diet with standard-of-care chemoimmunotherapy	LKB1-specific metabolic vulnerabilities, SOC	LUAD	Terminated due to low recruitment
NCT04265534	Telaglenastat with standard-of-care chemoimmunotherapy	GLS1, SOC	Non-squamous NSCLC	Terminated due to lack of clinical benefit
NCT03872427	Telaglenastat hydrochloride (CB-839 HCl)	GLS1	Solid tumors or malignant peripheral nerve sheath tumors	Active
NCT03334617	Durvalumab and olaparib	PD-1, PARP	NSCLC	Active, results available
NCT04173507	Talazoparib with avelumab	PARP, PD-L1	Non-squamous NSCLC	Completed: Did not meet the threshold for efficacy
NCT05445843	JDQ443	KRASG12C	NSCLC	Active
NCT05276726	JAB-21822	KRASG12C	NSCLC	Active
NCT06495125	Defactinib and avutometinib with nivolumab	FAK, RAK/MEK, PD-1	NSCLC	Recruiting
NCT05469178	Bemcentinib with standard-of-care immunotherapy	AXL, SOC	NSCLC	Terminated
NCT06219174	Difluoromethylornithine with pembrolizumab	ODC, PD-1	NSCLC	Recruiting
NCT05887492	TNG260 with pembrolizumab	CoREST, PD-1	Solid tumors	Recruiting
NCT05807048	Daratumumab	CD38	NSCLC	Recruiting
NCT05704634	Sarilumab with cemiplimab	IL-6R, PD-1	NSCLC	Active
NCT06331650	Carbognilumab with chemotherapy	CTLA-4, PD-1, Chemo	NSCLC	Recruiting
NCT06008093	Durvalumab and tremelimumab with chemotherapy	CTLA-4, PD-1, Chemo	Non-squamous NSCLC	Recruiting
NCT06335355	Adebrelimab and SHR-8068 with chemotherapy	CTLA-4, PD-L1, Chemo	NSCLC	Not yet recruiting
NCT06124963	WX390 and Toripalimab	PI3K, mTOR, PD-1	Gastric-type Endocervical Adenocarcinoma	Recruiting

SOC indicates Standard-of-Care when not detailed in trial description.

Chemo indicates chemotherapy when not further detailed in trial description.